摘要
目的:比较文拉法辛缓释剂和帕罗西汀治疗惊恐障碍的有效性和安全性。方法:将73例符合CCMD-3R的惊恐障碍病人随机分为2组,分别给予文拉法辛(38例,初始剂量75 mg·d^(-1))和帕罗西汀(35例,初始剂量10 mg·d^(-1))。采用惊恐症状评定量表(PASS)、汉密尔顿焦虑量表(HAMA)、临床总体印象量表(CGI)和不良反应量表(TESS)分别在治疗前,治疗后wk 2、4、8末各评定1次,并进行对比分析。结果:2组间在治疗后wk 2、4末PASS、HAMA、CGI评分有显著差异(P<0.05);在wk 8末2组间差异无显著意义(P>0.05);文拉法辛组PASS、HAMA、CGI评分在治疗后wk 2末比治疗前明显降低(P<0.05),在wk 4、8末有进一步改善(P<0.01);帕罗西汀组PASS、HAMA、CGI评分在治疗后wk 4、8末与治疗前相比均降分明显(P<0.01)。2组不良反应发生率无显著差异。结论:文拉法辛是一种快速有效且安全性较高的治疗惊恐障碍的药物。
AIM： To assess the efficacy and safety of venlafaxine extended release in the treatment of panic disorder. METHODS： Seventy-three patients met with CCMD-3R criteria for panic disorder were randomly allocated to two groups and were treated with venlafaxine extended release （38 patients） or paroxetine （35 patients） . The curative effects were assessed by PASS, HAMA, CGI and TESS before treatment and at the end of wk 2, 4 and 8 of the trial, respectively. RESULTS ： There was significant difference in PASS, HAMA and CGI at the end of wk 2, 4 after the treatment between two groups （P 〈 0.05）, and there was no significant difference at the end of wk 8 （P 〉 0.05） . PASS, HAMA and CGI in venlafaxine group decreased at the end of wk 2 （P 〈 0.05）, and wk 4, 8 （P 〈 0.01） . PASS, HAMA and CGI in paroxetine group decreased at the end of wk 4, 8 （P 〈 0.01 ） . There was no significant difference of the adverse drug reactions between the two groups. CONCLUSION ： Venlafaxine is a fast, effective and safe drug in the treatment of panic disorder.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2007年第10期768-771,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
惊恐病
文拉法辛
帕罗西汀
随机对照试验
panic disorder
venlafaxine
paroxetine
randomized controlled trails
作者简介
刘力（1970-）女，辽宁辽中人，主治医师，硕士，主要从事精神疾病临床及脑功能成像方面的研究。[联系人]刘力。Phn：86-13386886236。E—mail：ykdx@sohu．com
